Empreses emergents
2016
MODIS THERAPEUTICSDesenvolupant tractaments per a malalties genètiques rares. Empresa adquirida per Zogenix https://zogenix.com/ per 250 milions d'euros (2019).
Adreça
13th Street 409, 94612, Estats Units d'Amèrica
Propietat CERCA
Barcelona, Spain
2002
Vall d’Hebron Institut de Recerca (VHIR)
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
Modis Therapeutics is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need. We were formed in 2016 through a collaboration with academic experts in mitochondrial biology. Our lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease.
ABOUT TK2 DEFICIENCY - A progressive, devastating mitochondrial disease
Thymidine kinase 2 deficiency is a genetic disorder that results in mitochondrial dysfunction, leading to inadequate energy production in cells. TK2d causes progressive and severe muscle weakness, respiratory insufficiency, loss of motor function, and is often fatal.
ABOUT TK2 DEFICIENCY - A progressive, devastating mitochondrial disease
Thymidine kinase 2 deficiency is a genetic disorder that results in mitochondrial dysfunction, leading to inadequate energy production in cells. TK2d causes progressive and severe muscle weakness, respiratory insufficiency, loss of motor function, and is often fatal.
Descripció del producte
Modis' lead product is MT1621, a deoxynucleoside combination therapy, in advanced development, for the treatment of thymidine kinase 2 deficiency (TK2d).
Empresa tancada o sortida